MARKET

PLRX

PLRX

Pliant Therapeutics, Inc.
NASDAQ
1.470
-0.020
-1.34%
After Hours: 1.540 +0.07 +4.76% 19:54 03/26 EDT
OPEN
1.500
PREV CLOSE
1.490
HIGH
1.520
LOW
1.420
VOLUME
1.47M
TURNOVER
--
52 WEEK HIGH
16.52
52 WEEK LOW
1.260
MARKET CAP
90.02M
P/E (TTM)
-0.4232
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PLRX last week (0317-0321)?
Weekly Report · 3d ago
HC Wainwright & Co. Reiterates Neutral on Pliant Therapeuticsto Neutral
Benzinga · 03/18 15:53
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
Benzinga · 03/17 17:39
PLIANT THERAPEUTICS: ANTITUMOR ACTIVITY SEEN WITH CONFIRMED PARTIAL RESPONSES IN 50% OF PATIENTS AT HIGHEST DOSE TESTED TO DATE
Reuters · 03/17 12:09
PLIANT THERAPEUTICS INC: PLN-101095 WAS GENERALLY WELL TOLERATED ACROSS ALL DOSES
Reuters · 03/17 12:09
PLIANT THERAPEUTICS INC: ANNOUNCES INTERIM PHASE 1 DATA FOR PLN-101095 IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-REFRACTORY ADVANCED SOLID TUMORS
Reuters · 03/17 12:09
Weekly Report: what happened at PLRX last week (0310-0314)?
Weekly Report · 03/17 09:03
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement In Response To Recent Accumulations Of Its Common Stock
Benzinga · 03/13 11:23
More
About PLRX
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Webull offers Pliant Therapeutics Inc stock information, including NASDAQ: PLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLRX stock methods without spending real money on the virtual paper trading platform.